Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

August 7, 2025

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 12 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning, everyone. I'm Stephen, and I'll be serving as your conference operator for today's session. I'd like to extend a welcome to all of you joining Cronos Group's 2025 Second Quarter Earnings Conference Call. Please be aware that this call is being recorded today. Right now, I'll hand things over to Harrison Aaron, Senior Director, Investor Relations and Corporate Development. Harrison, the floor is yours.

Harrison Aaron

executive
#2

Thank you, Stephen, and thanks to everyone for being with us today as we go over Cronos' financial and business results for the second quarter of 2025. With me on this call are Mike Gorenstein, our Chairman, President and CEO, and Anna Shlimak, our CFO. This morning Cronos put out a news release announcing our financial results, and it has been filed on our EDGAR and SEDAR profiles. That information, along with the prepared remarks, will also be posted on our website under Investor Relations. Before I hand things over to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Such forward-looking statements rest on management's current expectations and assumptions, which are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ materially from expectations are detailed in our earnings materials and our SEC filings that are available on our website, and any forward-looking statements made during this call are qualified in their entirety by those documents. Information about non-GAAP financial measures, including reconciliations to U.S. GAAP, can also be found in the earnings materials available on our website. Finally, throughout this conference call we will be making statements regarding market share information.

Harrison Aaron

executive
#3

And unless noted differently, Hifyre supplies all market share figures. We're going to give our prepared remarks now, after which we'll take questions in a Q&A session. So with that, I'll hand things over to Mike Gorenstein, Chairman, President and CEO of Cronos.

Mike Gorenstein

executive
#4

Thanks, Harrison, and good morning to all of you. Cronos Group's core business keeps delivering solid results, powered by strong demand in key markets and product categories. Even with constraints on flower supply, our net revenue rose 21% versus the prior year, which includes consolidating GrowCo. The robust demand for our flower shows how well our focus on creating best-in-class borderless products is working. We're glad to see operating fundamentals keep improving through the first half, and we stay focused on our main goals for the year: launching the expanded cultivation capacity at GrowCo, strengthening our share position in Canada once that extra supply is available, continuing to expand in higher-margin international markets, and staying disciplined on costs. Our Spinach brand remains a standout, finishing Q2 as the #2 cannabis brand in Canada with a 4.7% market share across formats. Within flower, Spinach came in at #3 with 4.9% market share, even as ongoing supply constraints kept us from fully satisfying demand. That limited availability mirrors just how popular our flower products are. Our team is allocating inventory strategically to keep top-selling SKUs available while getting ready to unlock substantial added capacity via the GrowCo expansion.

Mike Gorenstein

executive
#5

We expect the first flower sales from that expansion to start this fall. And when the new capacity is fully up and running, it will help us satisfy demand and get growth accelerating again. In vapes, Spinach took the #4 spot overall with 6.5% share. And in the vape cartridge segment, Spinach sits at #2 with 8.4% share, with the Spinach Pink Lemonade vape standing as the best-selling 1.2 gram vape cartridge in Canada. We're very happy with how strong we are in vapes and can't wait to bring innovative products to this category. We keep showing robust consumer demand and brand strength in edibles, with five Spinach gummies among the top 10 of all edible products in Canada. Our industry-leading gummies held an impressive 20% market share in Q2, which underscores our ongoing leadership in innovative, high-quality cannabis edibles and reflects strong consumer loyalty to Spinach-branded products. Our Lord Jones brand has reinforced its premium positioning by launching concentrates. We recently introduced Lord Jones Live Resin Caviar, featuring standout offerings such as Gorilla Grape and Orange Velvet. These high-terpene, no-compromise extracts combine premium strains with state-of-the-art hardware, giving discerning consumers a refined and flavorful experience. The Lord Jones brand continues to lead the hash-infused pre-roll segment with 28.5% market share in Q2.

Mike Gorenstein

executive
#6

Later this month, we will introduce Live Resin Caviar-infused pre-rolls, which takes the Lord Jones lineup into fresh high-end market segments and reinforces our position as a leader in premium pre-rolls. Turning to the international part of our business. In Israel, both our core medical brand PEACE NATURALS and our value brand Lit keep expanding. Cronos Israel delivered yet another record quarter, with revenue up 36% year-over-year, as we continued gaining share in a competitive and evolving market. Based on pharmacy data Cronos collected, PEACE NATURALS finished the quarter as the #1 flower brand in Israel, holding well over 20% market share. Under both the PEACE NATURALS and Lit brands, Cronos Israel brought several new flower strains to market in Q2, strengthening its best-selling product portfolio. During our last quarter, we talked about the proposed duty on Canadian medical cannabis imports into Israel, and I want to give you an update. In April 2025, Israel's Finance Minister rejected that proposed duty, which led to an attempted legal challenge. In a July 2025 decision, the Israel Ministry of Justice concluded that the Minister of Finance had vetoed the proposed duty as invalid. We are extremely pleased that the proposed duty was vetoed. For nearly a decade, we have been investing and operating in Israel, which has helped us become the top medical cannabis provider there.

Mike Gorenstein

executive
#7

Our dedication to Israel's medical cannabis patients hasn't wavered, and for us Q2 marked a second straight quarter of record results. We support a market structure that is fair and equitable for the benefit of Israel's medical cannabis patients, and we'll keep advocating for patient access along with fair competition. On the international side, PEACE NATURALS keeps expanding. Germany stands out as a leading market and contributed more than any other to year-over-year revenue growth across the business as a whole. Even though proposed changes to the regulatory framework emerged over the past month, we still see potential for continued growth for our products in Germany. In Switzerland, flower under the PEACE NATURALS brand can now be obtained through that country's medical cannabis network. We brought PEACE NATURALS to Malta as well in June. And as Australia increases distribution, our core medical brand has reached 7 key global markets, among them Canada, Israel, Germany, the U.K., Australia, Switzerland and Malta. Supplying global medical markets with Cronos' portfolio of products is a central focus for us, and we're pleased to report that our distribution continues to expand every quarter. Cronos holds the industry's strongest balance sheet, with no debt and cash equivalents and short-term investments totaling $834 million, which strengthens our capacity to invest in growth, innovation and global expansion.

Mike Gorenstein

executive
#8

At this point I'll hand things over to Anna, who will take you through the financial results for the second quarter.

Anna Shlimak

executive
#9

Thanks, Mike, and good morning. I'll walk you through the results for the second quarter of 2025 now. Consolidated net revenue came in at $33.5 million for the company, up 21% compared with the same period a year earlier. At Cronos, leaving out GrowCo, net revenue reached $31.2 million, which works out to 13% growth year-over-year. GrowCo posted net revenue of $2.2 million in Q2 2025. Broadly speaking, and as of last quarter, the rise in consolidated net revenue came mainly from stronger flower sales in international markets and Israel, from consolidating GrowCo, and from greater extract sales in Canada. Gross profit for the second quarter was $14.5 million, which equates to a 43% gross margin — a substantial gain over the 23% recorded in Q2 2024. That year-over-year gross margin gain came about because of the GrowCo consolidation, higher average sales prices stemming from regional mix shifts, and production efficiencies. Operating expenses, before restructuring costs, totaled $19.1 million during the quarter, down $2.3 million year-over-year, and that decline was driven by a $2.2 million year-over-year reduction in G&A. Although operating expenses were lower year-over-year across the first half, we anticipate OpEx will be roughly flat year-over-year through the second half of 2025. Adjusted EBITDA for the second quarter was $1.7 million, which is an improvement of $12.7 million year-over-year, driven by the revenue and margin-enhancing consolidation of GrowCo, a revenue mix shift toward higher-priced non-Canadian markets — with Israel and International accounting for 43% of our revenue — and reductions in operating expenses.

Anna Shlimak

executive
#10

Now moving on to the balance sheet and the cash flow statement. At the close of the quarter, cash, cash equivalents and short-term investments totaled $834 million, which represents a decline of $3.4 million relative to Q1 2025. That decrease was primarily attributable to roughly $7 million of net working capital outflow, along with capital expenditure and share repurchases of about $4 million apiece. These pressures were partly offset by positive operating cash flow prior to working capital changes of approximately $10 million, plus an FX benefit of roughly $2 million. During July, we made an $18.5 million investment in High Tide by way of a 5-year convertible loan. That loan carries a face value of $22 million, features a 16% original issue discount, and pays interest quarterly at 4% of the loan's face value per annum. Should conversion not occur, we anticipate a yield to maturity of about 8%. Subject to mutual agreement between Cronos and High Tide, conversion into High Tide equity is possible at CAD 4.20 per share. In addition, alongside this investment we obtained a 5-year common share purchase warrant, exercisable for as many as 3.84 million High Tide common shares at CAD 3.91 per warrant share. To wrap up, we delivered another robust quarter, reflecting sustained growth and ongoing enhancement of our operating fundamentals, even with the flower supply constraints we have faced.

Anna Shlimak

executive
#11

We’re eager for GrowCo’s expansion to bring Fall 2025 flower sales, which should ease these supply limitations and support additional growth for our business. With that, I’d like to return the floor to Mike for a short remark ahead of Q&A.

Mike Gorenstein

executive
#12

So to close things out, what we delivered this quarter shows that the core business at Cronos is both strong and resilient. With leading brands such as Spinach and Lord Jones, plus growing international momentum behind PEACE NATURALS, our medical brand, and the GrowCo capacity expansion, we're positioned well to capture growth on both the top and bottom lines. We have confidence in our strategy and are excited about what lies ahead for the remainder of 2025. Thank you, and we'll now open up the call for questions.

Operator

operator
#13

Thank you. <<operator_script>> All right. At this moment, I see no questions. I want to express our thanks for joining today's conference. That brings the program to a close. You're free to disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.